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ABSTRACT
Gastrointestinal cancer is one of the health problems which is frequently found in many people in the world 
until now. Studies in gastrointestinal cancer showed early detection can reduce morbidity and improve the 
survival of patients. The precancerous lesions of the gastrointestinal tract are highly potential turn into cancer. 
Precancerous lesions can be defined as a change or non-cancerous lesions that can become cancerous over time. 
Precancerous lesions can be found on the entire upper and lower gastrointestinal tract. Precancerous lesions of 
the upper digestive tract that can be found are Barrett's esophagus, chronic gastritis with or without Helicobacter 
pylori infection, atrophic gastritis, intestinal metaplasia of the gastric mucosa, epithelial dysplasia, and adenoma 
polyp. While precancerous lesions in the lower gastrointestinal tract are adenoma, inflammatory bowel disease, 
chronic infection and hereditary non-polyposis colon lesions. Precancerous lesions of the stomach in the form of 
chronic atrophic gastritis, intestinal metaplasia and dysplasia can be treated with anti-inflammatory and anti-
free radical drugs such as rebamipide and superoxide dysmutase. Precancerous lesions in the colon in the form 
of chronic enterocolitis, dysplasia can be treated with anti-oxidants, anti-inflammatory and anti-free radical 
such as anti-oxidants, rebamipide, superoxide dismutase, anti-inflammatory drugs.
Keywords: precancerous lesions, gastrointestinal tract, intestinal metaplasia, dysplasia.
ABSTRAK
Kanker gastrointestinal merupakan salah satu masalah kesehatan yang sering ditemukan di dunia sampai 
sekarang. Studi pada kanker gastrointestinal menunjukkan bahwa deteksi dini dapat mengurangi morbiditas 
dan meningkatkan kelangsungan hidup pasien. Lesi prakanker pada saluran gastrointestinal sangat berpotensi 
berubah menjadi kanker. Lesi prakanker dapat didefinisikan sebagai lesi non-kanker yang bisa berubah menjadi 
kanker seiring dengan berjalannya waktu. Lesi prakanker dapat ditemukan pada semua saluran gastrointestinal 
bagian atas dan bawah. Lesi prakanker saluran pencernaan bagian atas yang dapat ditemukan adalah Esofagus 
Barrett, gastritis kronis dengan atau tanpa infeksi Helicobacter pylori, gastritis atrofi, “intestinal metaplasia” 
mukosa lambung, displasia epitel, dan polip adenoma. Sementara lesi prakanker di saluran cerna bagian bawah 
adalah adenoma, penyakit radang usus besar, infeksi kronis dan lesi usus besar non-poliposis bawaan. Lesi 
prakanker pada lambung berupa gastritis atrofik kronis, metaplasia usus dan displasia dapat diobati dengan 
obat anti radikal bebas/ anti-inflamasi seperti rebamipide dan superoxide dysmutase. Lesi prakanker di usus 
besar dalam bentuk enterokolitis kronis, displasia dapat diobati dengan anti-oksidan, anti-inflamasi dan anti-
radikal bebas seperti anti oksidan, rebamipide, superoxide dismutase, obat anti-inflamasi.
Kata kunci: lesi prakanker, saluran gastrointestinal, metaplasia intestinal, displasia
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INTRODUCTION
Gastrointestinal cancer is one of the health problems 
which are frequently found in many people in the world 
until now. Gastrointestinal cancer mortality rate is still 
high enough, despite there are already advance medical 
technologies and good medications for gastrointestinal 
disease.1 From the studies in gastrointestinal cancer, 
early detection can reduce morbidity and improve the 
survival of patients.1
 Gastrointestinal cancers arise through a cascade of 
precursor that is already known about inflammatory 
– ranging from metaplasia-dysplasia-carcinoma 
sequence, so it is always via the stages of precancerous 
lesions.2 The precancerous lesions of the gastrointestinal 
tract are highly potential turn into cancer. The task is to 
find precancerous lesions of the gastrointestinal tract as 
early as possible, so that we can prevent the occurrence 
of cancer of the gastrointestinal tract.3 
DEFINITION OF PRECANCEROUS LESIONS
Precancerous lesions can be defined as a change or 
a non-cancerous lesions that can become cancerous 
over time.4 Precancerous lesion is a common condition 
associated with increased risk to turn into cancer. If left 
untreated the condition will turn into cancer.
TYPES AND CLASSIFICATION OF PRECANCEROUS 
LESIONS
Precancerous lesions can be found on the entire 
upper and lower gastrointestinal tract. Precancerous 
lesions of the upper digestive tract that can be found are 
Barrett's esophagus, chronic gastritis with or without 
Helicobacter pylori infection, atrophic gastritis, 
intestinal metaplasia of the gastric mucosa, epithelial 
dysplasia, and adenoma polyp.2,3,5,6 
While gastrointestinal precancerous lesions that can 
be found in the lower gastrointestinal tract are adenoma 
(tubular, tubulovillous and villous), inflammatory 
bowel disease (including Crohn's disease and ulcerative 
colitis), chronic infection and hereditary non-polyposis 
colon lesions.3,6 
Chronic atrophic gastritis should be diagnosed 
and graded on the basis of the presence of chronic 
inflammatory cells, including lymphocytes and 
plasma cells that expand the lamina propria, and the 
disappearance of the normal glands.7-9 In the gastric 
body/fundus this is associated with a loss of specialized 
cells and thus a reduction of gastric secretory functions. 
The severity of gland loss (atrophy) should be graded 
although inter- and intraobserver agreement are both 
poor.
EPIDEMIOLOGY
Studies in the world revealed that the annual 
incidence of gastric cancer from atrophic gastritis, 
intestinal metaplasia and dysplasia, ranging from 0-2%, 
0-10% and 0-73%.10 A study from the Netherland found 
that the annual incidence of gastric cancer is 0.1% for 
patients with atrophic gastritis, 0.25% for intestinal 
metaplasia, 0.6% for mild-to-moderate dysplasia 
and 6% for severe dysplasia within 5 years after 
diagnosis.1 Risk factors for gastric cancer increased 
the severity of gastric premalignant lesions at the time 
of initial diagnosis, for example, severe dysplasia 
(HR = 40.14, 95%), Increased age (75-84 years, 
HR = 3.75, 95%), and male gender (HR = 1.50). The 
authors concluded from this study that patients with 
premalignant gastric lesions are at increased risk of 
gastric cancer.1
A population study in Shandong province of 
China with gastroscopy examination found that the 
prevalence of chronic atrophic gastritis 98%, gastric 
intestinal metaplasia obtained 33%, 20% gastric 
dysplasia. Found no sex differences in the prevalence 
of chronic atrophic gastritis. The prevalence of 
intestinal metaplasia and dysplasia lesions increased 
significantly corresponding increase in age.11
Colorectal adenomatous polyp has chance to 
develop into carcinoma about 0.25% per year; the 
transformation rate is proportional with the size of 
adenoma. Adenomas with size less than 1 cm had 
much lower chance to transform into carcinoma 
compared with adenomas sized > 2 cm (1% vs. 50%). 
The tubulovillous and villous adenoma polyp had 50% 
chance for developing colorectal cancer. The colorectal 
adenoma can be found as incidental findings during 
colonoscopy screening in 40% of people older than 60 
years old.12 Study from Korea showed that patients with 
ulcerative colitis had cumulative risk of developing 
colorectal cancer for 0.7% at 10 years, 7.9% at 20 
years, and 33.2% at 30 years.13 Meta-analysis showed 
that the cumulative risk of developing colorectal cancer 
following diagnosis of Chron’s disease is 2.9%.14
PATHOGENESIS
The changes from normal lesions become 
precancerous lesions and then into gastrointestinal 
cancers triggered by many factors such as. genetics, 
infection (e.g. Helicobacter pylori infection in gaster, 
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intestinal tuberculosis infection, etc.), inflammation(e.g. 
Crohn's disease, ulcerative colitis), diet, stress (anxiety, 
depression), and oxidative stress or free radicals.15-17 
Chronic inflammation cells will produce 
microenvironment that may promote the cancer 
development and progression.18 Prolonged and 
overproduction of cytokines e.g. Tumor Necrosis 
Factor (TNF-α), interleukin-6 (IL-6) may induce the 
production of free radical agents such as reactive 
oxygen and nitrogen species (ROS and NOS). ROS 
and NOS will induce DNA damage, genomic instability 
and alter the transcription factors (nuclear factor-kB), 
signaling proteins, carcinogenesis factors (p53, DNA 
Mismatch Repair proteins).12,18-20 Proinflammatory 
cytokines may act as tumor growth factor, therefore 
may induce proliferation of tumor cells. Chronic 
inflammation also can induce epithelial mesenchymal 
transition, angiogenesis, and metastasis.18 
SUPPORTING EXAMINATION
Supporting examinations used for diagnosis or 
screening and follow-up of precancerous lesions of 
the gastrointestinal tract are endoscopy, histopathology 
examination, examination miRNA.3,9,21 Gastrointestinal 
endoscopy must be done regularly and consists of 
esophagogastroduodenoscopy, colonoscopy and 
enteroscopy with Chromo-endoscopy staining 
(blue methylen, indigocarmine, Lugol) or Narrow 
band imaging technique (NBI) or endo-microscopy 
examinations. Histopathology examination is an 
important examination that should be performed 
to diagnose the presence of precancerous lesions. 
Histopathology examination of mucosal biopsies 
obtained through the digestive tract. Histopathology 
examination was performed with specific staining such 
as Haematoxylin-eosin (to detect intestinal metaplasia, 
dysplasia), PAS and HID Alcian blue Alcian blue 
(to detect subtypes of intestinal metaplasia) or other 
staining.9 Examination of endo-microscopy performed 
using confocal laser endomicroscope Pentax or with 
Cellvizio probe-based optical mini microscope.22-25 
MiRNA expression can differentiate normal to 
pathological lesions, and among precancerous lesions, 
it may be able to classify different subtypes.3 
MANAGEMENT
The diagnosis of precancerous lesions of the GI tract 
is done by history taking of the patients complaints & 
clinical manifestations, family history of GI tract cancer, 
physical examination and supporting examinations.26 
Supporting examinations which is necessary include 
blood hemoglobin level, erythrocyte sedimentation rate 
(ESR), C reactive protein (CRP), stool examination 
i.e. Fecal occult blood (stool occult blood test), fecal 
calprotectin and fecal M2 Pyruvate Kinase (M2PK).26-
28 Examination with high sensitivity and specificity 
close to 100% to diagnose precancerous lesion/
cancer are esophagogastroduodenoscopy examination, 
colonoscopy, enteroscopy, Chromo-endoscopy and 
confocal laser endomicroscopy with biopsy examination 
and histopathology examination.21,29 These supporting 
examinations must be performed periodically to monitor 
the progress of precancerous lesions. 
European Society of Gastroenterology (ESGE), 
EHSG, ESP and SPED proposed the management 
of precancerous conditions and lesions in the 
stomach.2 Conventional white light endoscopy can 
not accurately differentiate between and diagnose pre-
neoplastic gastric conditions/lesions. Magnification 
chromoendoscopy or narrow-band imaging (NBI) 
endoscopy with or without magnification may be 
offered in these cases as it improves diagnosis of such 
lesions. At least four biopsies of the proximal and 
distal stomach, on the lesser and greater curvature, 
are needed for adequate assessment of premalignant 
gastric conditions.2 Systems for histopathological 
staging (e.g. operative link for gastritis assessment 
and operative link for gastric intestinal metaplasia 
assessment) may be useful for identifying subgroups 
of patients with different risks of progression to 
gastric cancer, namely those with extensive lesions 
(i.e., atrophy and/or intestinal metaplasia in both 
antrum and corpus). Low serum pepsinogen levels 
can also predict this phenotype and, in such patients, 
Helicobacter pylori serology may be useful for further 
detection of high risk individuals. Family history of 
gastric cancer, neither age, gender, H. pylori virulence 
factors, or host genetic variations change these clinical 
recommendations.2 Patients with extensive atrophy 
and/or extensive intestinal metaplasia should be offered 
endoscopic surveillance every 3 years. Patients with 
mild to moderate atrophy/intestinal metaplasia only in 
antrum do not need follow-up. If Helicobacter pylori 
infection is present, eradication should be offered to 
prevent high grade dysplasia or carcinoma. Currently, 
the use of cyclooxygenase-2 (COX-2) inhibitors or 
the use of dietary supplementation with antioxidants 
(ascorbic acid and beta-carotene) are not endorsed 
as approaches to decrease the risk of progression of 
gastric precancerous lesions. Patients with dysplasia 
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without a visible endoscopic lesion should be closely 
followed up, either immediately and 6 to 12 months 
thereafter, or within 12 months, for those with high 
grade or low grade dysplasia. Those with dysplasia or 
cancer within an endoscopically visible lesion should 
undergo staging and resection.2
Precancerous lesions of the stomach in the form 
of chronic atrophic gastritis, intestinal metaplasia and 
dysplasia can be treated with anti-inflammatory and anti-
free radical drugs such as rebamipide and superoxide 
dysmutase (SOD).30-32 Chronic gastritis caused by 
Helicobacter pylori infection must get an eradication 
therapy for H. pylori.33 The principle of eradication 
therapy for Helicobacter pylori divided into triple and 
quadruple therapy. Triple therapy consisted of proton 
pump inhibitor and 2 antibiotics. Quadruple therapy 
consisted of bismuth agent (bismuth subcitrate etc), 
proton pump inhibitor and 2 antibiotics. The proton pump 
inhitors which can used are omeprazole, lansoprazole, 
rabeprazole, pantoprazole, esomeprazole, tenatoprazole. 
Antibiotics that can eradicate Helicobacter pylori 
infection are amoxicillin, clarithromycin, metronidazole, 
azithromycin, tetracycline, and levofloxacin.33,34 
Precancerous lesions in the colon in the form of chronic 
enterocolitis, dysplasia can be treated with anti-oxidants, 
anti-inflammatory and anti-free radical al anti-oxidants 
(vitamin A, vitamin C, vitamin E, polyphenols 
and astaxantin), rebamipide, superoxide dismutase 
(SOD), anti-inflammatory drugs (sulfasalazine, 
mesalamine/5-ASA, corticosteroid), aspirin).30-32,35-42 
Chronic infections in the intestine must be treated 
with antibiotics according to the cause of infection. 
If the cause is tuberculosis infection, the patient 
must be treated with anti tuberculosis drugs for 9-12 
months. The anti tuberculosis drugs are isoniazid, 
rifampicine, ethambuthol, pirazinamide, etc.43,44 
Adenoma polyp in the gaster, small intestine and colon 
must be removed by endoscopic polypectomy as soon 
as possible.45,46 
ALGORITHM OF MANAGEMENT OF PRECANCEROUS 
LESIONS OF THE GI TRACT
 European Society of Gastroenterology(ESGE), 
EHSG, ESP and SPED proposed an algorithm 
(flowchart) for the management of precancerous 
lesions of the gaster.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Several biopsies should be obtained 
(≥2 in antrum and ≥2 in 
corpus;lesser and greater curvature) 
Spread of lesion Grade of dysplasia 
Mild/moderat
e atrophic 
gastritis or 
intestinal 
metaplasia 
only in 
antrum 
Atrophic 
gastritis or 
intestinal 
metaplasia 
both in antrum 
and corpus 
Low grade High grade 
H.pylori eradication 
Follow-up Staging 
& 
Immediately and 6-12 
months 
<12 months 
Patients with atrophic gastritis 
and/or intestinal metaplasia without 
dysplasia 
Patients with dysplasia 
Extension Visible endoscopic lesion? 
Magnification chromoendoscopy and/or narrow band imaging (NBI) may be offered 
Every 3 years 
Figure 1. Algorithm (flowchart) for the management of precancerous lesions of the 
gaster[cited from 2]
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World Gastroenterology Organization recommends 
guidelines for colon cancer and precancerous colon 
lesions, namely: (1) screening test with a stool test, the 
fecal occult blood test and fecal DNA; (2) screening test 
with endoscopy/colonoscopy and CT colonography.47
CONCLUSION
Precancerous lesions of the gastrointestinal tract are 
lesions that can turn into cancer. Detection, diagnosis, 
and treatment of precancerous lesions have to be 
done as early as possible so that we can prevent the 
occurrence of gastric cancer. 
REFERENCES
1. de Vries AC, van Grieken NC, Looman CW, Casparie MK, de 
Vries E, Meijer GA, et al. Gastric cancer risk in patients with 
premalignant gastric lesions: a nationwide cohort study in the 
Netherlands. Gastroenterology 2008;134:945-52.
2. Dinis-Ribeiro M, Areia M, de Vries AC, Marcos-Pinto R, 
Monteiro-Soares M, O'Connor A, et al. Management of 
precancerous conditions and lesions in the stomach (MAPS): 
guideline from the European Society of Gastrointestinal 
Endoscopy (ESGE), European Helicobacter Study Group 
(EHSG), European Society of Pathology (ESP), and the 
Sociedade Portuguesa de Endoscopia Digestiva (SPED). 
Endoscopy 2012;44:74-94.
3. Fassan M, Croce CM, Rugge M. miRNAs in precancerous 
lesions of the gastrointestinal tract. World J Gastroenterol 
2011;17:5231-9.
4. Precancerous Skin Lesions and Skin Cancer Slideshow [serial 
online] [cited 2017 April 30]. Available from: URL: http://
www.webmd.com/melanoma-skin-cancer/ss/slideshow-skin-
lesions-and-cancer
5. Morson BC. Precancerous lesions of upper gastrointestinal 
tract. Jama 1962;179:311-5.
6. Haziri A, Juniku-Shkololli A, Gashi Z, Berisha D, Haziri A. 
Helicobacter pylori infection and precancerous lesions of the 
stomach. Medicinski Arhiv 2010;64:248-9.
7. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and 
grading of gastritis. The updated Sydney System. International 
Workshop on the Histopathology of Gastritis, Houston 1994. 
The American Journal of Surgical Pathology 1996;20:1161-81.
8. Misiewicz JJ. The Sydney System: a new classification 
of gastritis. Introduction. Journal of Gastroenterology and 
Hepatology 1991;6:207-8.
9. Plummer M, Buiatti E, Lopez G, Peraza S, Vivas J, Oliver 
W, et al. Histological diagnosis of precancerous lesions of 
the stomach: a reliability study. International Journal of 
Epidemiology 1997;26:716-20.
10. de Vries AC, Haringsma J, Kuipers EJ. The detection, surveillance 
and treatment of premalignant gastric lesions related to 
Helicobacter pylori infection. Helicobacter 2007;12:1-15.
11. You WC, Blot WJ, Li JY, Chang YS, Jin ML, Kneller R, et 
al. Precancerous gastric lesions in a population at high risk of 
stomach cancer. Cancer Research 1993;53:1317-21.
12. Conteduca V, Sansonno D, Russi S, Dammacco F. Precancerous 
colorectal lesions (Review). International Journal of Oncology 
2013;43:973-84.
13. Kim BJ, Yang SK, Kim JS, Jeen YT, Choi H, Han DS, et 
al. Trends of ulcerative colitis-associated colorectal cancer 
in Korea: A KASID study. Journal of Gastroenterology and 
Hepatology 2009;24:667-71.
14. Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal 
and small bowel cancer risk in patients with Crohn's disease. 
Alimentary Pharmacology & Therapeutics 2006;23:1097-104.
15. Suzuki H, Nishizawa T, Tsugawa H, Mogami S, Hibi T. Roles 
of oxidative stress in stomach disorders. Journal of Clinical 
Biochemistry and Nutrition 2012;50:35-9.
16. Head KA, Jurenka JS. Inflammatory bowel disease Part 1: 
ulcerative colitis--pathophysiology and conventional and 
alternative treatment options. Alternative medicine review : 
a Journal of Clinical Therapeutic 2003;8:247-83.
17. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal 
cancer in inflammatory bowel disease: the role of inflammation. 
American journal of physiology Gastrointestinal and Liver 
Physiology 2004;287:G7-17.
18. Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, 
Hermoso MA. Chronic inflammation and cytokines in the 
tumor microenvironment. Journal of Immunology Research 
2014;2014:149185.
19. Grivennikov SI, Greten FR, Karin M. Immunity, Inflammation, 
and Cancer. Cell 2010;140:883-99.
20. Sandouk F, Al Jerf F, Al-Halabi MHDB. Precancerous Lesions 
in Colorectal Cancer. Gastroenterology Research and Practice 
2013;2013:457901.
21. Chung C-S, Wang H-P. Screening for Precancerous Lesions 
of Upper Gastrointestinal Tract: From the Endoscopists' 
Viewpoint. Gastroenterology Research and Practice 
2013;2013:681439.
22. Al-Kawas FH. Detecting recurrence after EMR of colon 
neoplasia: is confocal laser endomicroscopy the answer? Close 
but no cigar! Gastrointestinal Endoscopy 2012;75:534-6.
23. Shahid MW, Buchner AM, Heckman MG, Krishna M, 
Raimondo M, Woodward T, et al. Diagnostic accuracy of 
probe-based confocal laser endomicroscopy and narrow band 
imaging for small colorectal polyps: a feasibility study. The 
American Journal of Gastroenterology 2012;107:231-9.
24. Shahid MW, Buchner AM, Raimondo M, Woodward TA, 
Krishna M, Wallace MB. Accuracy of real-time vs. blinded 
offline diagnosis of neoplastic colorectal polyps using 
probe-based confocal laser endomicroscopy: a pilot study. 
Endoscopy 2012;44:343-8.
25. Wang KK, Carr-Locke DL, Singh SK, Neumann H, Bertani 
H, Galmiche J-P, et al. Use of probe-based confocal laser 
endomicroscopy (pCLE) in gastrointestinal applications. A 
consensus report based on clinical evidence. United European 
Gastroenterology Journal 2015;3:230-54.
26. U. S. Preventive Services Task Force. Screening for colorectal 
cancer: Us preventive services task force recommendation 
statement. Jama 2016;315:2564-75.
27. Parente F, Marino B, Ilardo A, Fracasso P, Zullo A, Hassan 
C, et al. A combination of faecal tests for the detection of 
colon cancer: a new strategy for an appropriate selection of 
referrals to colonoscopy? A prospective multicentre Italian 
study. European Journal of Gastroenterology & Hepatology 
2012;24:1145-52.
28. Rutka M, Bor R, Bálint A, Fábián A, Milassin Á, Nagy F, et 
al. Diagnostic Accuracy of Five Different Fecal Markers for 
the Detection of Precancerous and Cancerous Lesions of the 
Colorectum. Mediators of Inflammation 2016;2016:2492081.
Volume 18, Number 2, August 2017 117
Precancerous Lesions in Gastrointestinal Tract
29. Trivedi PJ, Braden B. Indications, stains and techniques in 
chromoendoscopy. QJM: An International Journal of Medicine 
2013;106:117-31.
30. Hahm KB, Lee KJ, Kim JH, Cho SW, Chung MH. 
Helicobacter pylori infection, oxidative DNA damage, gastric 
carcinogenesis, and reversibility by rebamipide. Digestive 
Diseases and Sciences 1998;43:72s-7s.
31. Robbins D, Zhao Y. Manganese Superoxide Dismutase 
in Cancer Prevention. Antioxidants & Redox Signaling 
2014;20:1628-45.
32. Correa P, Piazuelo MB, Camargo MC. The future of gastric 
cancer prevention. Gastric cancer : official journal of the 
International Gastric Cancer Association and the Japanese 
Gastric Cancer Association 2004;7:9-16.
33. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley 
NJ, et al. Second Asia-Pacific Consensus Guidelines for 
Helicobacter pylori infection. Journal of Gastroenterology 
and Hepatology 2009;24:1587-600.
34. Hunt RH, Xiao SD, Megraud F, Leon-Barua R, Bazzoli F, 
van der Merwe S, et al. Helicobacter pylori in developing 
countries. World Gastroenterology Organisation Global 
Guideline. Journal of Gastrointestinal and Liver Diseases 
2011;20:299-304.
35. Dangles O. Antioxidant Activity of Plant Phenols: Chemical 
Mechanisms and Biological Significance. Current Organic 
Chemistry 2012;16:692-714.
36. Grune T, Lietz G, Palou A, Ross AC, Stahl W, Tang G, et al. 
β-Carotene is an important vitamin A source for humans. The 
Journal of Nutrition 2010;140:2268S-85S.
37. Park JS, Chyun JH, Kim YK, Line LL, Chew BP. Astaxanthin 
decreased oxidative stress and inflammation and enhanced 
immune response in humans. Nutrition & Metabolism 
2010;7:18.
38. Nakajima Y, Inokuchi Y, Shimazawa M, Otsubo K, Ishibashi 
T, Hara H. Astaxanthin, a dietary carotenoid, protects retinal 
cells against oxidative stress in-vitro and in mice in-vivo. The 
Journal of Pharmacy and Pharmacology 2008;60:1365-74.
39. Dobis DR, Sawyer RT, Gillespie MM, Newman LS, Maier 
LA, Day BJ. Sulfasalazine and mesalamine modulate 
beryllium-specific lymphocyte proliferation and inflammatory 
cytokine production. American Journal of Respiratory Cell 
and Molecular Biology 2010;43:458-64.
40. Nanda K, Moss AC. Update on the management of ulcerative 
colitis: treatment and maintenance approaches focused on 
MMX(®) mesalamine. Clinical Pharmacology: Advances and 
Applications 2012;4:41-50.
41. Wendland BE, Aghdassi E, Tam C, Carrrier J, Steinhart AH, 
Wolman SL, et al. Lipid peroxidation and plasma antioxidant 
micronutrients in Crohn disease. The American Journal of 
Clinical Nutrition 2001;74:259-64.
42. Hanauer SB. New steroids for IBD: progress report. Gut 
2002;51:182-3.
43. Joshi JM. Tuberculosis chemotherapy in the 21(st) century: 
Back to the basics. Lung India : Official Organ of Indian Chest 
Society 2011;28:193-200.
44. Donoghue HD, Holton J. Intestinal tuberculosis. Current 
Opinion in Infectious Diseases 2009;22:490-6.
45. Gallegos-Orozco JF, Gurudu SR. Complex Colon Polypectomy. 
Gastroenterology & Hepatology 2010;6:375-82.
46. Rosa I, Fidalgo P, Soares J, Vinga S, Oliveira C, Silva JP, 
et al. Adenoma incidence decreases under the effect of 
polypectomy. World J Gastroenterol 2012;18:1243-8.
47. Winawer S, Classen M, Lambert R, Fried M, Dite P, Goh 
KL, et al. World Gastroenterology Organisation/International 
Digestive Cancer Alliance Practice Guidelines: Colorectal 
Cancer Screening.: World Gastroenterology Organisation; 
2007 [serial online] [cited 2017 April 30]. Available from: 
URL: http://www.worldgastroenterology.org/UserFiles/file/
guidelines/colorectal-cancer-screening-english-2007.pdf
